Multicenter, Single-Arm Phase II Study of Nab-Paclitaxel/Carboplatin in Untreated PS2 Patients with Advanced NSCLC: TORG1426

被引：0
|
作者：
Naoki, K. [1 ]
Ichikawa, Y. [2 ]
Bessho, A. [3 ]
Hosokawa, S. [3 ]
Shimokawa, T. [4 ]
Yomota, M. [5 ]
Hosomi, Y. [5 ]
Otani, S. [1 ]
Nakahara, Y. [1 ]
Iwasawa, S. [6 ]
Tokito, T. [7 ]
Seki, N. [2 ]
Okamoto, H. [8 ]
机构：
[1] Kitasato Univ, Sch Med, Resp Med, Sagamihara, Kanagawa, Japan
[2] Teikyo Univ, Div Med Oncol, Dept Internal Med, Sch Med, Tokyo, Japan
[3] Japanese Red Cross Okayama Hosp, Resp Med, Okayama, Japan
[4] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan
[5] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[6] Chiba Univ, Chiba, Japan
[7] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan
[8] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; performance status; nab-Paclitaxel;
D O I：
10.1016/j.jtho.2019.08.730
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-15
引用
收藏
页码：S361 / S361
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study
    An, Jusheng
    Li, Xiumin
    Wang, Jing
    Zhu, Lijing
    An, Ruifang
    Jiang, Kui
    Huang, Yi
    Wang, Ke
    Li, Guiling
    Wang, Chunyan
    Yuan, Jianlin
    Hou, Xiaoli
    Yang, Guiyu
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    Wu, Lingying
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Phase I/II Study of Carboplatin Plus Weekly Nab-Paclitaxel in Aged ≥75 Patients with Squamous-Cell Lung Cancer: TORG1322
    Zenke, Y.
    Niho, S.
    Umemura, S.
    Ishihara, M.
    Ochiai, R.
    Nogami, N.
    Hosomi, Y.
    Shimokawa, T.
    Tokito, T.
    Goto, Y.
    Miura, Y.
    Saito, H.
    Hida, N.
    Ikeda, S.
    Tanaka, H.
    Furuya, N.
    Misumi, T.
    Ohe, Y.
    Okamoto, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S302 - S302
  • [43] Nab-paclitaxel as second line treatment in advanced gastric cancer: A HORG multicenter phase II study
    Katsaounis, P.
    Kentepozidis, N.
    Kotsakis, A.
    Polyzos, A.
    Vamvakas, L.
    Bakogiorgos, M.
    Boukovinas, I.
    Hartabilas, E.
    Prinarakis, E.
    Skaltsi, T.
    Georgoulias, V.
    Souglakos, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results
    Gentzler, R. D.
    Mohindra, N. A.
    Hanna, N.
    Chae, Y. K.
    Jalal, S. I.
    Hall, R.
    Villaflor, V. M.
    Reckamp, K. L.
    Koczywas, M.
    Sullivan, D.
    Wood, L.
    Patel, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 236 - 236
  • [45] Frontline therapy of anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib in patients with newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study.
    Jiang, Yi
    Cheng, Wenjun
    Gao, Yingchun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NAC-GA trial)
    Okada, Ken-ichi
    Kimura, Kenjiro
    Yamashita, Yo-Ichi
    Shibuya, Kazuto
    Matsumoto, Ippei
    Satoi, Sohei
    Yoshida, Kazuhiro
    Kodera, Yasuhiro
    Akahori, Takahiro
    Hirono, Seiko
    Eguchi, Hidetoshi
    Asakuma, Mitsuhiro
    Tani, Masaji
    Hatano, Etsuro
    Ikoma, Hisashi
    Ohira, Go
    Hayashi, Hiromitsu
    Wan, Ke
    Shimokawa, Toshio
    Kawai, Manabu
    Yamaue, Hiroki
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (06): : 997 - 1008
  • [47] Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Eguchi, Susumu
    Inomata, Masafumi
    Nishihara, Kazuyoshi
    Shinchi, Hiroyuki
    Okuda, Koji
    Baba, Hideo
    Nagano, Hiroaki
    Ueki, Toshiharu
    Noshiro, Hirokazu
    Nakamura, Masafumi
    INTERNATIONAL JOURNAL OF SURGERY PROTOCOLS, 2021, 25 (01): : 55 - 60
  • [48] Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322
    Zenke, Yoshitaka
    Niho, Seiji
    Umemura, Shigeki
    Ishihara, Masashi
    Seki, Nobuhiko
    Nogami, Naoyuki
    Hosomi, Yukio
    Shimokawa, Tsuneo
    Tokito, Takaaki
    Goto, Yasushi
    Miura, Yosuke
    Saito, Haruhiro
    Hida, Naoya
    Ikeda, Satoshi
    Tanaka, Hiroshi
    Furuya, Naoki
    Misumi, Toshihiro
    Yamanaka, Takeharu
    Ohe, Yuichiro
    Okamoto, Hiroaki
    LUNG CANCER, 2020, 146 : 182 - 188
  • [49] Gemcitabine plus Nab-paclitaxel as a second-line treatment for patients with advanced pancreatic cancer after FOLFIRINOX failure: a multicenter, single-arm, open-label, phase 2 trial
    Choi, Jin Ho
    Lee, Hee Seung
    Huh, Gunn
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 122
  • [50] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in advanced NSCLC: safety and efficacy results
    Waterhouse, David M.
    George, Ben
    Gutierrez, Martin
    Otterson, Greg A.
    Ko, Amy
    Ong, Teng Jin
    Stergiopoulos, Sotirios
    Trunova, Nataliya
    Kelly, Karen
    CANCER RESEARCH, 2016, 76
12345